Purple Biotech Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PPBT research report →
Price Chart
About the company
Purple Biotech Ltd. , a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1).
- CEO
- Isaac Israel
- IPO
- 2015
- Employees
- 10
- HQ
- Rehovot, TA, IL
Get TickerSpark's AI analysis on PPBT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $210.58K
- P/E
- -0.77
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 2.21
- EV/EBITDA
- 0.17
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -224.86%
- ROIC
- -245.06%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-27,458,000
- Net Income
- $-26,386,000-264.4%
- EPS
- $-5.50-24.4%
- OCF Growth
- +61.5%
- FCF Growth
- +61.4%
- 52W High
- $8.90
- 52W Low
- $0.91
- 50D MA
- $1.38
- 200D MA
- $2.68
- Beta
- -0.55
- RSI (14)
- 58
- Avg Volume
- 1.26M
No earnings-call transcripts are available for PPBT yet.
- Free Float
- 94.5%
- Shares Outstanding
- 138.08K
- Float Shares
- 130.52K
of shares held by institutions
12 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Smartharvest Portfolios, LLC | 51.27K | ▲ 22.80K |
| Hrt Financial LP | 18.23K | ▲ 3.59K |
| Two Sigma Advisers, LP | 14.70K | ▲ 14.70K |
| Jane Street Group, LLC | 14.00K | ▲ 14.00K |
| Ubs Group AG | 6.47K | ▲ 5.72K |
| Rhumbline Advisers | 850 | ▼ 6 |
| Bnp Paribas Financial Markets | 400 | ▲ 400 |
| Morgan Stanley | 300 | ▲ 103 |
| Caitong International Asset Management Co., Ltd | 78 | ▲ 78 |
| Northwestern Mutual Wealth Management Co | 8 | 0 |
| Ifg Advisory, LLC | 7 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Rock Simcha | other | 0 |
| Mar 18, 26 | Rock Simcha | other | 0 |
| Mar 18, 26 | Rock Simcha | other | 0 |
| Mar 18, 26 | Zilberberg Suzana | other | 0 |
| Mar 18, 26 | Zilberberg Suzana | other | 0 |
| Mar 18, 26 | Zilberberg Suzana | other | 0 |
| Mar 18, 26 | Zilberberg Suzana | other | 0 |
| Mar 18, 26 | Agmon Ido | other | 0 |
| Mar 18, 26 | Agmon Ido | other | 0 |
| Mar 18, 26 | Agmon Ido | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PPBT coverage
Recent articles, reports, and earnings notes.
No research on PPBT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PPBT report →Purple Biotech's IM1240, a CAPTN-3-Capped Tri-Specific T- and NK-Cell Engager Targeting 5T4, Shows Robust Tumor Killing in Immunotherapy-Resistant Cancer Models in Plenary Oral Presentation at EORTC-NCI-AACR Symposium
globenewswire.com · Nov 20
Purple Biotech Reports Third Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Nov 17
Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium
globenewswire.com · Oct 29
New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies
globenewswire.com · Sep 2
Financial Review: Ionis Pharmaceuticals (NASDAQ:IONS) & Purple Biotech (NASDAQ:PPBT)
defenseworld.net · Aug 31
Purple Biotech (PPBT) Expected to Announce Quarterly Earnings on Wednesday
defenseworld.net · Aug 4
Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window
globenewswire.com · Jun 11
Purple Biotech Regains Compliance with Nasdaq
globenewswire.com · Mar 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.